Johnson & Johnson $JNJ Stake Lessened by Van Hulzen Asset Management LLC

Key Points

• Van Hulzen Asset Management LLC has reduced its stake in Johnson & Johnson by 22.5%, now holding 118,842 shares valued at approximately $19.7 million.
• Johnson & Johnson reported earnings of $2.77 per share, exceeding analysts' expectations, and projected an EPS guidance of 10.800-10.900 for FY 2025.
• The company declared a quarterly dividend of $1.30, representing an annualized yield of 2.9%, with a payout ratio of 55.61%.

Van Hulzen Asset Management LLC lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 22.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 118,842 shares of the company's stock after selling 34,558 shares during the period. Johnson & Johnson comprises approximately 1.8% of Van Hulzen Asset Management LLC's portfolio, making the stock its 12th biggest position. Van Hulzen Asset Management LLC's holdings in Johnson & Johnson were worth $19,709,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Johnson & Johnson by 13.9% during the 4th quarter. Brighton Jones LLC now owns 51,876 shares of the company's stock valued at $7,502,000 after buying an additional 6,332 shares during the period. Hudson Value Partners LLC increased its stake in shares of Johnson & Johnson by 2.5% in the fourth quarter. Hudson Value Partners LLC now owns 41,403 shares of the company's stock worth $5,648,000 after acquiring an additional 1,022 shares during the last quarter. Burling Wealth Partners LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at $3,908,000. Integrated Wealth Concepts LLC grew its stake in Johnson & Johnson by 6.1% in the fourth quarter. Integrated Wealth Concepts LLC now owns 108,473 shares of the company's stock valued at $15,687,000 after purchasing an additional 6,247 shares in the last quarter. Finally, Empire Financial Management Company LLC increased its position in Johnson & Johnson by 18.0% in the 4th quarter. Empire Financial Management Company LLC now owns 17,882 shares of the company's stock worth $2,586,000 after purchasing an additional 2,732 shares during the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of JNJ opened at $178.8990 on Friday. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $180.61. The company's fifty day moving average is $163.04 and its 200-day moving average is $159.05. The company has a quick ratio of 0.76, a current ratio of 1.01 and a debt-to-equity ratio of 0.50. The firm has a market cap of $430.85 billion, a price-to-earnings ratio of 19.13, a price-to-earnings-growth ratio of 2.28 and a beta of 0.41.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its earnings results on Wednesday, July 16th. The company reported $2.77 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. During the same period last year, the business posted $2.82 EPS. Johnson & Johnson's revenue was up 5.8% compared to the same quarter last year. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Equities analysts expect that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, August 26th. This represents a $5.20 dividend on an annualized basis and a yield of 2.9%. Johnson & Johnson's dividend payout ratio (DPR) is presently 55.61%.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the company. Barclays boosted their price target on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research note on Thursday, July 17th. Guggenheim restated a "neutral" rating and set a $167.00 price target (up previously from $164.00) on shares of Johnson & Johnson in a research note on Thursday, July 17th. Royal Bank Of Canada increased their price target on shares of Johnson & Johnson from $181.00 to $185.00 and gave the stock an "outperform" rating in a research note on Thursday, July 17th. Leerink Partners lowered shares of Johnson & Johnson from an "outperform" rating to a "market perform" rating and dropped their price target for the stock from $169.00 to $153.00 in a research note on Tuesday, May 13th. Finally, Benchmark upgraded shares of Johnson & Johnson to a "strong-buy" rating in a research note on Thursday, April 24th. Two analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and nine have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $176.29.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.